Private company

SQZ Biotechnologies Co

American biological products company, incorporated in Delaware1

In its 2023 annual report the company says: “SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients.”45 It is headquartered in Watertown, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWatertown, Massachusetts1
  • Incorporated inDE2
  • Business address200 Arsenal Yards Blvd., Ste. 210, Watertown, Ma 024722
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-375.7%Operating margin3
-370.0%Net margin3
-20.7%Revenue growth, 20223
-139.0%Return on equity3
-$84.1MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development73¢$71.0M
  • Selling, general and admin27¢$26.3M

Out of $21.5M in revenue.3 The company lost money this year.

Financial statements

Revenue453$21.5M in 2022+7% since 2019
0$10.0M$20.0M$30.0M2019: $20.1M$20.1M20192020: $21.0M$21.0M2020+4%2021: $27.1M$27.1M2021+29%2022: $21.5M$21.5M2022−21%
Operating income453-$80.7M in 2022+135% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$34.3M-$34.3M20192020: -$51.1M-$51.1M2020+49%2021: -$68.8M-$68.8M2021+35%2022: -$80.7M-$80.7M2022+17%
Net income453-$79.5M in 2022+147% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$32.2M-$32.2M20192020: -$50.5M-$50.5M2020+57%2021: -$68.7M-$68.7M2021+36%2022: -$79.5M-$79.5M2022+16%
Fiscal year20182019202020212022
Revenue$20.1M4$21.0M5$27.1M3$21.5M3
Research and development$36.1M4$51.5M5$70.1M3$71.0M3
Selling, general and admin$18.3M4$20.5M5$25.7M3$26.3M3
Operating expenses$95.9M3$102.2M3
Operating income-$34.3M4-$51.1M5-$68.8M3-$80.7M3
Income tax$04$05$03$03
Net income-$32.2M4-$50.5M5-$68.7M3-$79.5M3
Earnings per share-$2.493-$2.763
Earnings per share (diluted)-$2.493-$2.763
Shares (weighted, basic)27.6M shares328.8M shares3
Shares (weighted, diluted)27.6M shares328.8M shares3

Compare SQZ Biotechnologies Co with another company

Corporate structure

SQZ Biotechnologies Co sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SQZ Biotechnologies Co

  • Artal International S.C.A. Filed SC 13G/A on SQZ Biotechnologies Co, latest Feb 9, 2024 (2 filings since Feb 13, 2023)
  • 683 Capital Management, LLC Filed SC 13G/A on SQZ Biotechnologies Co, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • NanoDimension II Management Ltd Filed SC 13G/A on SQZ Biotechnologies Co, latest Feb 14, 2023 (2 filings since Feb 10, 2022)
  • Temasek Holdings (Private) Ltd Filed SC 13G/A on SQZ Biotechnologies Co, latest Feb 14, 2022
  • Polaris Management Co. VII, L.L.C. Filed SC 13D/A on SQZ Biotechnologies Co, latest Feb 11, 2022
  • SQZ Biotechnologies Co Watertown, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SQZ Biotechnologies Co reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$6.8M3 Dec 31, 2022$6.7M3 Dec 31, 2021+2.7%
Furniture and fixtures$319.0K3 Dec 31, 2022$319.0K3 Dec 31, 20210%
Leasehold improvements$579.0K3 Dec 31, 2022$579.0K3 Dec 31, 20210%
Property and equipment, before depreciation$7.7M3 Dec 31, 2022$7.6M3 Dec 31, 2021+2.4%
Accumulated depreciation$5.8M3 Dec 31, 2022$4.5M3 Dec 31, 2021+28.1%
Property and equipment, net$2.0M3 Dec 31, 2022$3.0M3 Dec 31, 2021−35.7%
Operating-lease assets (leased space)$27.4M3 Dec 31, 2022$69.8M3 Dec 31, 2021−60.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$63.7M3 Dec 31, 2022$143.5M3 Dec 31, 2021−55.6%

Leadership

Who has led SQZ Biotechnologies Co, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Armon Sharei2020–2022

President

  1. Armon Sharei2020–2022

Chief financial officer

  1. Teri Loxam2020–2021
  2. Micah Zajic2022
2025
Board members and other officers (17)

Timeline

  1. Dec 22, 20238-K Entered a material agreement28
  2. Oct 2, 20238-K Exit or restructuring costs; Impairment; Executive or director change29
  3. Sep 15, 20238-K Ended a material agreement30
  4. Jul 25, 20238-K Other events31
  5. Jul 7, 20238-K Executive or director change32
  6. Jul 3, 20238-K Listing notice or transfer; Other events33
  7. Jun 15, 20238-K Listing notice or transfer; Shareholder vote; Other events34
  8. Apr 10, 20238-K Executive or director change35
  9. Jan 18, 20238-K Listing notice or transfer; Regulation FD disclosure36
  10. Dec 6, 20228-K Other events37
  11. Nov 30, 20228-K Exit or restructuring costs; Executive or director change; Regulation FD disclosure38
  12. Sep 6, 20228-K Executive or director change; Regulation FD disclosure39
  13. Oct 29, 2020New chief executive Armon Sharei becomes CEO9

Filings

99 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 22 major events, 44 insider forms, 8 large holders, 16 other. The latest 20:

  1. Feb 9, 2024SC 13G/A EDGAR
  2. Jan 23, 2024DEFM14A EDGAR
  3. Jan 12, 2024PREM14A EDGAR
  4. Jan 4, 202415-12G EDGAR
  5. Dec 22, 20238-K EDGAR
  6. Dec 1, 2023EFFECT EDGAR
  7. Nov 30, 2023POS AM EDGAR
  8. Nov 30, 2023S-8 POS EDGAR
  9. Nov 8, 202310-Q EDGAR
  10. Oct 2, 20238-K EDGAR
  11. Sep 15, 20238-K EDGAR
  12. Aug 10, 202310-Q EDGAR
  13. Jul 25, 20238-K EDGAR
  14. Jul 7, 20238-K EDGAR
  15. Jul 3, 20238-K EDGAR
  16. Jun 15, 20234 FORM 4 SUBMISSION EDGAR
  17. Jun 15, 20234 FORM 4 SUBMISSION EDGAR
  18. Jun 15, 20234 FORM 4 SUBMISSION EDGAR
  19. Jun 15, 20234 FORM 4 SUBMISSION EDGAR
  20. Jun 15, 20234 FORM 4 SUBMISSION EDGAR

The 99 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 15, 2022Capasso RichardSee RemarksSale1,183$3.33$3.9KForm 4
May 25, 2022Jensen Klavs F.DirectorBuy14,326$3.52$50.4KForm 4
Dec 13, 2021SCHULMAN AMY WDirectorBuy3,700$10.91$40.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How SQZ Biotechnologies Co is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSQZ Biotechnologies Co1
  • CIK0001604477
  • Employer ID (EIN)46-24311151
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address200 Arsenal Yards Blvd., Ste. 210, Watertown, MA 024721
  • Phone617-898-88241
  • Shares outstanding29,491,125 as of Oct 31, 20238
  • Public float$80.3M as of Jun 30, 20223
  • On EDGAR sinceApr 3, 20141
  • Filings228 in all: 4 (82), 8-K (29), 3 (25), SC 13G/A (12), 10-Q (10), CORRESP (7), SC 13G (6), D (5)1
    All 37 form types

    UPLOAD (5), EFFECT (4), 10-K (3), DEF 14A (3), DEFA14A (3), DRSLTR (3), 4/A (2), 424B4 (2), 8-K/A (2), D/A (2), DRS (2), DRS/A (2), S-1 (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), ARS (1), CERT (1), DEFM14A (1), POS AM (1), PRE 14A (1), PREM14A (1), S-1/A (1), S-3 (1), S-8 (1), S-8 POS (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 22, 2023
    Quarterly report (10-Q) Nov 8, 2023
    Proxy statement (DEF 14A) Apr 26, 2023
    Latest 8-K (8-K) Dec 22, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45